Abstract | BACKGROUND: METHODS: RESULTS: Between Feb 2 and March 15, 2020, 26 patients were recruited; 14 were randomly assigned to the combination group, 7 were assigned to the favipiravir group and 5 were assigned to the tocilizumab group. The cumulative lung lesion remission rate at day 14 was significantly higher in combination group as compared with favipiravir group (P = 0.019, HR 2.66 95 % CI [1.08-6.53]). And there was also a significant difference between tocilizumab and favipivavir (P = 0.034, HR 3.16, 95 % CI 0.62-16.10). In addition, there was no significant difference between the combination group and the tocilizumab group (P = 0.575, HR 1.28 95 %CI 0.39-4.23). Furthermore, combined therapy can also significantly relieve clinical symptoms and help blood routine to return to normal. No serious adverse events were reported. CONCLUSION:
|
Authors | Hong Zhao, Qi Zhu, Chi Zhang, Jiawen Li, Ming Wei, Yuhong Qin, Guilin Chen, Ke Wang, Junhua Yu, Zhao Wu, Xianxiang Chen, Guiqiang Wang |
Journal | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
(Biomed Pharmacother)
Vol. 133
Pg. 110825
(Jan 2021)
ISSN: 1950-6007 [Electronic] France |
PMID | 33378989
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Copyright | Copyright © 2020. Published by Elsevier Masson SAS. |
Chemical References |
- Amides
- Antibodies, Monoclonal, Humanized
- Antiviral Agents
- IL6 protein, human
- Interleukin-6
- Pyrazines
- Receptors, Interleukin-6
- favipiravir
- tocilizumab
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Amides
(administration & dosage, adverse effects, therapeutic use)
- Antibodies, Monoclonal, Humanized
(administration & dosage, adverse effects, therapeutic use)
- Antiviral Agents
(administration & dosage, adverse effects, therapeutic use)
- COVID-19
(diagnostic imaging, pathology, therapy)
- Drug Therapy, Combination
- Female
- Humans
- Interleukin-6
(blood)
- Kaplan-Meier Estimate
- Lung
(diagnostic imaging, pathology)
- Male
- Middle Aged
- Models, Immunological
- Pyrazines
(administration & dosage, adverse effects, therapeutic use)
- Receptors, Interleukin-6
(antagonists & inhibitors)
- Respiration, Artificial
(statistics & numerical data)
- SARS-CoV-2
(drug effects)
- Sample Size
- Treatment Outcome
- COVID-19 Drug Treatment
|